5-HT1a receptor subtype agonist

Details 5-HT1a receptor subtype agonist 5-HT1a receptor subtype agonist

2006-05-30

2006-05-30

Spivack, Phyllis (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07053092

ABSTRACT:
The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1Areceptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1):wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

REFERENCES:
patent: 4734416 (1988-03-01), Banno et al.
patent: 4764416 (1988-08-01), Ueyama et al.
patent: 4983607 (1991-01-01), Manoury et al.
patent: 5006528 (1991-04-01), Oshiro et al.
patent: 5162375 (1992-11-01), Nicholson et al.
patent: 5691330 (1997-11-01), Nakao et al.
patent: 0 226 441 (1987-06-01), None
patent: 0 360 077 (1990-03-01), None
patent: 0 367 141 (1990-05-01), None
patent: 0 565 274 (1993-10-01), None
patent: 9-40648 (1997-02-01), None
patent: 9 301 867 (1997-11-01), None
patent: 09 301867 (1997-11-01), None
patent: WO 92/10200 (1992-06-01), None
patent: WO 92/20655 (1992-11-01), None
patent: WO 93/04681 (1993-03-01), None
patent: WO 94/09765 (1994-05-01), None
patent: WO 94/13620 (1994-06-01), None
patent: WO 98/08817 (1998-03-01), None
patent: WO 99/38864 (1999-08-01), None
Yamada et al., Society for Neuroscience Abstracts (2000), 26 (1-2). No. -871.7.
Eric P.M. Prinseen et al., Interactions between neuroleptics and 5-HT1aligands in preclinical behavorial models for antipsychotic and extrapyramidal effects, Psychopharmacology, vol. 144, No. 1, May, 1999 (1999-05), pp. 20-29.
Uwahodo Yasufumi et al., “Pharmacological profile of OPC-145976, a novel antipsychotic drug (2); Weak extrapyramidal side effects.” Japanese Journal of Pharmacology, vol. 67, No. Suppl. 1, 1995, p. 144P.
S. Jordon et al., “In Vivo Effects of Aripiprazole on Dopaminergic and Serotonergic Function in Rat Prefrontal Cortex and Stiatum.” Society for Neuroscience Abstracts, Society of Neuroscience, US, vol. 2., No. 27, 2001, p. 2327, AN87503.
Jeffery A. Lieberman, “Atypical Antipsychotic Drug as a First-Line Treatment of Schizophrenia: A Rationale and Hypothesis,” Journal of Clinical Psychiatry, vol. 57, No. Suppl. 11, 1996, pp. 68-71.
Paul E. Keck, Jr., et al., “Bipolar Disorder,” Medical Clinics of North America, W. B. Saunders Company, Philadelphia, US., vol. 3, No. 85, May, 2001, pp. 645-661.
Maria-Garcia-Anaya et al., Los antipsycoticos atipicos: Una Revision, Salud Mental, vol. 24, No. 5, Oct. 2001, pp. 37-43.
Alfieri et al., “Comparative efficacy of a single oral dose of ondansetron and of buspirone against ciaplatin-induced emesis in cancer patients,” British Journal of Cancel, vol. 72, 1995, pp. 1013-1015.
L.R.C. Agnew et al., “Dorland's illustrated medical dictionary, 24thEdition,” 1965, W:B: Saunders Company, Philadelphia, page 1088.
U. L. Mullins et al., “Effects of Antidepressants on 5-HT7Receptor Regulation in the the RatHypothalamus,”) Neuropsychopharmacology, 1999, vol. 21, No. 3, pp. 352-367.
Scrip Newsletter (Oct.4, 2000) No. 2580, p. 11.
“Unique Pharmacological profile of a Novel Antiphyschotic Drug, Aripiprazole (OPC-14597)” M. Sasa et al., CNS Drug Reviews, 1997, vol. 3, No. 1, pp. 24-33.
“Alterations of Central Serotonin and Dopamine Turnover in Rats Treated with Ipsapirone and Other 5-hydroxytryptamine1AAgonists with Potential Anxiolytic Properties1, ” M. Hamon et al., J. Pharmacol.Exp. Ther., 1988, vol. 246, No. 2, pp. 745-752.
“Synthesis and Structure-Activity Relationship of Substituted Tetrahydro-and Hexahydro-1,2-benzisothiasol-3-one 1,1-Dioxides and Thiadiazinones: Potential Anxiolytic Agents,” M. Abou-Gharbia et al., J. Med. Chem., 1989, vo. 32, No. 5, pp. 1024-1033.
H. Y. Meltzer et al., “Multisystems and Circuitry Pharmacotherapy-Single or Multiple Receptor Targets: Which are Best for Antiphsychotic Drugs,” Neuropsychopharmacology, 2000, vol. 23, No. 52.

Affiliated with

Also associated with

Rating

5-HT1a receptor subtype agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-HT1a receptor subtype agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT1a receptor subtype agonist will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3545686